title: Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany.
abstract: The German Standing Committee on Vaccination (Ständige Impfkommission, STIKO) recommends vaccinating risk groups against hepatitis B and gives advice for postexposure prophylaxis. STIKO has recently revised this recommendation, focusing on: (i) classification of risk groups, (ii) duration of protection after primary immunization, and (iii) anti-HBs threshold that defines successful hepatitis B vaccination. Orientating literature reviews were performed for the first objective. Examples of population subgroups at increased risk were identified and classified into three indication groups. Systematic reviews on the duration of vaccine-induced protection identified one randomized controlled trial (RCT) and nine cohort studies. When applying the grading of recommendation, assessment, development, and evaluation (GRADE) methodology, evidence from RCTs was considered of very low quality regarding the question of whether hepatitis B can be prevented for 15 years after successful primary vaccination (anti-HBs ≥ 10 IU/l) with a vaccine efficacy of 96 % against chronic hepatitis, 89 % against HBsAg positivity, and 73 % against isolated anti-HBc positivity. However, seven cohort studies showed that no cases of clinical hepatitis B or HBsAg positivity occurred during a maximum follow-up period of 10 years in settings comparable to the situation in Germany when anti-HBs ≥ 10 IU/l was used to indicate vaccination success. Less than 1 % of vaccinated study participants had isolated anti-HBc positivity. GRADE assessment of two cohort studies revealed that evidence of very low quality exists that the use of anti-HBs ≥ 100 IU/l to measure vaccination success leads to a lower frequency of anti-HBc positivity during follow-up than the use of anti-HBs ≥ 10 IU/l. The recommendation was revised according to this evidence.
authors.affiliation: Immunization Unit, Department of Infectious Disease Epidemiology, Robert Koch Institute, Seestr. 10, 13353, Berlin, Germany, hardert@rki.de.
authors.forename: T
authors.initials: T
authors.lastname: Harder
authors.forename: C
authors.initials: C
authors.lastname: Remschmidt
authors.forename: G
authors.initials: G
authors.lastname: Falkenhorst
authors.forename: R
authors.initials: R
authors.lastname: Zimmermann
authors.forename: H
authors.initials: H
authors.lastname: Hengel
authors.forename: T
authors.initials: T
authors.lastname: Ledig
authors.forename: H
authors.initials: H
authors.lastname: Oppermann
authors.forename: S
authors.initials: S
authors.lastname: Zeuzem
authors.forename: S
authors.initials: S
authors.lastname: Wicker
mesh_terms: D019317:Evidence-Based Medicine; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000592:standards* / Q000627:therapeutic use*; D006801:Humans; D056990:Post-Exposure Prophylaxis / Q000592:standards*; D016896:Treatment Outcome; D014611:Vaccination / Q000592:standards*
chemical_list: D017325:Hepatitis B Vaccines